Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
Holding MRK?
Track your performance easily
MRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.14 - $134.63
Previous Close$115.86
Volume6.71M
Average Volume (3M)9.83M
Market Cap
$293.68B
Enterprise Value$320.18B
Total Cash (Recent Filing)$11.35B
Total Debt (Recent Filing)$37.79B
Price to Earnings (P/E)21.4
Beta0.14
Next Earnings
Oct 31, 2024EPS Estimate
$1.74Next Dividend Ex-Date
Sep 16, 2024Dividend Yield2.64%
Share Statistics
EPS (TTM)5.39
Shares Outstanding2,534,809,312
10 Day Avg. Volume9,499,659
30 Day Avg. Volume9,833,361
Standard Deviation0.06
R-Squared0.11
Alpha0.00484
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)4.65
Price to Cash Flow (P/CF)12.90
P/FCF Ratio15.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.12
Enterprise Value/Gross Profit7.28
Enterprise Value/Ebitda16.46
Forecast
1Y Price Target
$140.33Price Target Upside21.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMRK's 2Q24 total revenue of $16.1B beats by ~$200M, mainly driven by continued strong performance from Keytruda and Gardasil.
Pipeline DevelopmentMerck’s current small-cell lung cancer pipeline is exciting, with significant data expected to support accelerated approval.
Product LaunchWinrevair's launch better than the Street anticipated with a $70M print ahead of the Street’s $62M, though 60% of 2Q24 sales from stocking.
Bears Say
CompetitionSummit Therapeutics presented detailed data from their HARMONi-2 Phase 3 trial in PD-L1 positive NSCLC showing a statistically significant median PFS benefit compared to MRK's Keytruda.
Growth OutlookConcerns over Gardasil's (G9's) near-term growth within China (60-70% of ex-US G9 sales) was an unpleasant surprise that dampens MRK's growth.
SalesThe biggest reason for slowing Gardasil sales is that the bivalent vaccine is taking share, driven primarily by the bivalent being provided for free by local governments and charity organizations.
---
Ownership Overview
0.16% Insiders
22.21% Mutual Funds
34.66% Other Institutional Investors
42.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $99.14 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 31, 2024 which is in 46 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Jul 30, 2024. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.168 by $0.112.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.64%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $1.74.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,534,809,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.28 in its last earnings report, beating expectations of $2.168. Following the earnings report the stock price went down -9.806%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.33 (21.12% Upside)
$140.33 (21.12% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 220.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.33%
12-Months-Change
Fundamentals
Return on Equity
33.39%
Trailing 12-Months
Asset Growth
7.81%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
MRK Company Deck
---
MRK Earnings Call
Q2 2024
0:00 / 0:00
---
MRK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$140.33
▲(21.12% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
29/39 ratings generated profit
1 Year Average Return
+14.28%
reiterated a buy rating 4 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 74.36% of your transactions generating a profit, with an average return of +14.28% per trade.
---